Limits...
Model of life expectancy of chronic hepatitis B carriers in an endemic region.

Wang T - J Epidemiol (2009)

Bottom Line: When e antigen status remains positive, absolute liver mortality rates climb significantly after age 40 years.CLD is a proportionally higher threat for e antigen-negative females than for other subgroups.Males have higher liver-related mortality at all ages.

View Article: PubMed Central - PubMed

Affiliation: Faculty of Health Sciences, Queen's University, Kingston, ON, Canada. wang.tao@mail.com

ABSTRACT

Background: Chronic infection with hepatitis B (HBV) is a known risk factor for increased mortality from hepatocellular carcinoma (HCC) and chronic liver disease (CLD). However, the specific effects of chronic HBV infection on life expectancy have not been adequately studied. Taiwan is endemic for HBV infection, and thus provides sufficient information for such estimates.

Methods: Population mortality statistics, combined with data on the contribution of HBV to HCC and CLD deaths, were used to model carrier mortality by sex and e antigen status. An abridged life table was used to calculate carrier life expectancy.

Results: Among both males and females, those who are e antigen-positive are more likely to die from HCC than from CLD. When e antigen status remains positive, absolute liver mortality rates climb significantly after age 40 years. CLD is a proportionally higher threat for e antigen-negative females than for other subgroups. Males have higher liver-related mortality at all ages. A small decrease in life expectancy, from 82.0 to 80.1 years, was found for female noncarriers versus female carriers; a larger discrepancy was observed for males-from 76.2 to 71.8 years. In comparison to noncarriers, the lifetime relative risk of mortality is 1.35 for male carriers and 1.16 for female carriers.

Conclusions: These results indicate that chronic HBV infection results in significant liver-related mortality; however, carriers retain a satisfactory life expectancy.

Show MeSH

Related in: MedlinePlus

Survival of hepatitis B carriers versus noncarriers, by sex.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3924100&req=5

fig05: Survival of hepatitis B carriers versus noncarriers, by sex.

Mentions: The survival plot (Figure 5) shows that female HBV carriers experience a modest reduction in life expectancy, which shifts the mean life expectancy from 82.0 to 80.1 years. Among men, the effect is more pronounced, resulting in a loss of 4.4 years—from 76.2 to 71.8 years. The 75% survival mark is reached at age 62.8 years for male carriers, versus age 68.3 years in noncarriers. Among women, 75% of carriers survive to age 73.4 years, while 75% of noncarriers live to be 76.0 years.


Model of life expectancy of chronic hepatitis B carriers in an endemic region.

Wang T - J Epidemiol (2009)

Survival of hepatitis B carriers versus noncarriers, by sex.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3924100&req=5

fig05: Survival of hepatitis B carriers versus noncarriers, by sex.
Mentions: The survival plot (Figure 5) shows that female HBV carriers experience a modest reduction in life expectancy, which shifts the mean life expectancy from 82.0 to 80.1 years. Among men, the effect is more pronounced, resulting in a loss of 4.4 years—from 76.2 to 71.8 years. The 75% survival mark is reached at age 62.8 years for male carriers, versus age 68.3 years in noncarriers. Among women, 75% of carriers survive to age 73.4 years, while 75% of noncarriers live to be 76.0 years.

Bottom Line: When e antigen status remains positive, absolute liver mortality rates climb significantly after age 40 years.CLD is a proportionally higher threat for e antigen-negative females than for other subgroups.Males have higher liver-related mortality at all ages.

View Article: PubMed Central - PubMed

Affiliation: Faculty of Health Sciences, Queen's University, Kingston, ON, Canada. wang.tao@mail.com

ABSTRACT

Background: Chronic infection with hepatitis B (HBV) is a known risk factor for increased mortality from hepatocellular carcinoma (HCC) and chronic liver disease (CLD). However, the specific effects of chronic HBV infection on life expectancy have not been adequately studied. Taiwan is endemic for HBV infection, and thus provides sufficient information for such estimates.

Methods: Population mortality statistics, combined with data on the contribution of HBV to HCC and CLD deaths, were used to model carrier mortality by sex and e antigen status. An abridged life table was used to calculate carrier life expectancy.

Results: Among both males and females, those who are e antigen-positive are more likely to die from HCC than from CLD. When e antigen status remains positive, absolute liver mortality rates climb significantly after age 40 years. CLD is a proportionally higher threat for e antigen-negative females than for other subgroups. Males have higher liver-related mortality at all ages. A small decrease in life expectancy, from 82.0 to 80.1 years, was found for female noncarriers versus female carriers; a larger discrepancy was observed for males-from 76.2 to 71.8 years. In comparison to noncarriers, the lifetime relative risk of mortality is 1.35 for male carriers and 1.16 for female carriers.

Conclusions: These results indicate that chronic HBV infection results in significant liver-related mortality; however, carriers retain a satisfactory life expectancy.

Show MeSH
Related in: MedlinePlus